Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL
Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.